Intervention

[18F]GTP1

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

5 shown

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's DiseaseNCT04566003 · 2020-10-26

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese ParticipantsNCT04394845 · 2020-08-11

A Study of Semorinemab in Patients With Moderate Alzheimer's DiseaseNCT03828747 · 2019-01-25

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's DiseaseNCT03289143 · 2017-10-04

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy ParticipantsNCT02640092 · 2015-12-23

Common conditions

Alzheimer's Disease3 Alzheimer Disease1 Alzheimer Disease (AD)1

Leading sponsors

Genentech, Inc.5

Trial status mix

COMPLETED4

TERMINATED1

Phase mix

PHASE13

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.